Human CTLA-4 antibodies and their uses
AssigneeMedarex, Inc.
InventorsAlan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
Life of this patent
Estimating the term…
Abstract
The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
Claims33
A method for treating cancer in a subject, the method comprising administering to the subject an anti-CTLA-4 antibody or antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region that comprises CDR1, CDR2, and CDR3 domains;
- and a light chain variable region that comprises CDR1, CDR2, and CDR3 domains, wherein the heavy chain variable region and light chain variable region CDR3 domains are selected from the group consisting of:
- (a) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:37;
- and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:35;
- and
- (b) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:38;
- and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:36;
- and binds to human CTLA-4 with a binding affinity of about 108 M−1 or greater.
A method for treating cancer in a subject, the method comprising administering to the subject an antibody or antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof
- competes for binding to a human CTLA-4 polypeptide with a reference antibody comprising the amino acid sequence set forth in SEQ ID NO:
- 17, and the amino acid sequence set forth in SEQ ID NO:
- 7;
- and
- has a binding affinity of about 108 M−1 or greater.
A method for treating cancer in a subject, the method comprising administering to the subject an anti-CTLA-4 antibody or antigen-binding portion thereof, comprising:
- (a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS:
- 27, 32 and 37, respectively;
- and
- (b) a light chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS:
- 24, 29 and 35, respectively.
A method for treating cancer in a subject, the method comprising administering to the subject an anti-CTLA-4 antibody or antigen-binding portion thereof, comprising:
- (a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS:
- 27, 33 and 37, respectively;
- and
- (b) a light chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS:
- 25, 30 and 35, respectively.
A method for treating cancer in a subject, the method comprising administering to the subject an anti-CTLA-4 antibody or antigen-binding portion thereof, comprising:
- (a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS:
- 28, 34 and 38, respectively;
- and
- (b) a light chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS:
- 26, 31 and 36, respectively.
A method for treating cancer in a subject, the method comprising administering to the subject an anti-CTLA-4 antibody or antigen-binding portion thereof comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
- 17 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
- 7.
A method for treating cancer in a subject, the method comprising administering to the subject an anti-CTLA-4 antibody or antigen-binding portion thereof comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
- 19 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
- 9.
A method for treating cancer in a subject, the method comprising administering to the subject an anti-CTLA-4 antibody or antigen-binding portion thereof comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
- 23 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
- 13.
Dependencies are inferred from the claim text.